Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.09
ARRY's Cash to Debt is ranked lower than
79% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ARRY: 1.09 )
Ranked among companies with meaningful Cash to Debt only.
ARRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 3.34 Max: No Debt
Current: 1.09
Equity to Asset 0.03
ARRY's Equity to Asset is ranked lower than
92% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARRY: 0.03 )
Ranked among companies with meaningful Equity to Asset only.
ARRY' s Equity to Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.27 Max: 0.93
Current: 0.03
-1.55
0.93
F-Score: 6
Z-Score: -2.50
M-Score: 5.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.02
ARRY's Operating margin (%) is ranked higher than
64% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ARRY: -10.02 )
Ranked among companies with meaningful Operating margin (%) only.
ARRY' s Operating margin (%) Range Over the Past 10 Years
Min: -410.11  Med: -105.86 Max: 3.18
Current: -10.02
-410.11
3.18
Net-margin (%) 0.60
ARRY's Net-margin (%) is ranked higher than
69% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ARRY: 0.60 )
Ranked among companies with meaningful Net-margin (%) only.
ARRY' s Net-margin (%) Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: 0.6
-511.63
18.05
ROE (%) 1.94
ARRY's ROE (%) is ranked higher than
76% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. ARRY: 1.94 )
Ranked among companies with meaningful ROE (%) only.
ARRY' s ROE (%) Range Over the Past 10 Years
Min: -132.15  Med: -55.01 Max: 110.67
Current: 1.94
-132.15
110.67
ROA (%) 0.22
ARRY's ROA (%) is ranked higher than
76% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ARRY: 0.22 )
Ranked among companies with meaningful ROA (%) only.
ARRY' s ROA (%) Range Over the Past 10 Years
Min: -99.03  Med: -48.04 Max: 5.6
Current: 0.22
-99.03
5.6
ROC (Joel Greenblatt) (%) 109.12
ARRY's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ARRY: 109.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -829.85  Med: -239.15 Max: 297.05
Current: 109.12
-829.85
297.05
Revenue Growth (3Y)(%) -32.80
ARRY's Revenue Growth (3Y)(%) is ranked lower than
79% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARRY: -32.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.9  Med: -6.05 Max: 39.8
Current: -32.8
-35.9
39.8
» ARRY's 10-Y Financials

Financials (Next Earnings Date: 2016-05-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ARRY Guru Trades in Q2 2015

Jim Simons 811,995 sh (-23.01%)
» More
Q3 2015

ARRY Guru Trades in Q3 2015

Paul Tudor Jones 11,500 sh (New)
Ken Fisher 135,695 sh (New)
Jim Simons 929,428 sh (+14.46%)
» More
Q4 2015

ARRY Guru Trades in Q4 2015

Steven Cohen 952,200 sh (New)
Paul Tudor Jones 107,347 sh (+833.45%)
Jim Simons 3,210,394 sh (+245.42%)
Ken Fisher 135,695 sh (unchged)
» More
Q1 2016

ARRY Guru Trades in Q1 2016

Ken Fisher 135,695 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 80.73
ARRY's P/B is ranked lower than
98% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ARRY: 80.73 )
Ranked among companies with meaningful P/B only.
ARRY' s P/B Range Over the Past 10 Years
Min: 2.28  Med: 6.59 Max: 107.8
Current: 80.73
2.28
107.8
P/S 6.76
ARRY's P/S is ranked higher than
65% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ARRY: 6.76 )
Ranked among companies with meaningful P/S only.
ARRY' s P/S Range Over the Past 10 Years
Min: 1.43  Med: 6.88 Max: 24.26
Current: 6.76
1.43
24.26
EV-to-EBIT 42.40
ARRY's EV-to-EBIT is ranked lower than
66% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. ARRY: 42.40 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -34.5  Med: -5.50 Max: 320.9
Current: 42.4
-34.5
320.9
EV-to-EBITDA 33.89
ARRY's EV-to-EBITDA is ranked lower than
65% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. ARRY: 33.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.9  Med: -6.55 Max: 165.9
Current: 33.89
-59.9
165.9
Current Ratio 3.62
ARRY's Current Ratio is ranked lower than
58% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARRY: 3.62 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.80 Max: 7.86
Current: 3.62
0.81
7.86
Quick Ratio 3.62
ARRY's Quick Ratio is ranked lower than
56% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARRY: 3.62 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.80 Max: 7.55
Current: 3.62
0.81
7.55
Days Sales Outstanding 335.17
ARRY's Days Sales Outstanding is ranked lower than
93% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. ARRY: 335.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 44.35 Max: 497.21
Current: 335.17
2.06
497.21
Days Payable 142.62
ARRY's Days Payable is ranked higher than
74% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. ARRY: 142.62 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 69.05 Max: 124.01
Current: 142.62
37.58
124.01

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 82.75
ARRY's Price/Tangible Book is ranked lower than
97% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ARRY: 82.75 )
Ranked among companies with meaningful Price/Tangible Book only.
ARRY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.14  Med: 4.11 Max: 102.93
Current: 82.75
1.14
102.93
Price/Median PS Value 0.99
ARRY's Price/Median PS Value is ranked higher than
52% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ARRY: 0.99 )
Ranked among companies with meaningful Price/Median PS Value only.
ARRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.96 Max: 3.18
Current: 0.99
0.21
3.18
Price/Graham Number 7.52
ARRY's Price/Graham Number is ranked lower than
99.99% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. ARRY: 7.52 )
Ranked among companies with meaningful Price/Graham Number only.
ARRY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.24  Med: 0.79 Max: 10.36
Current: 7.52
0.24
10.36
Earnings Yield (Greenblatt) (%) 2.31
ARRY's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ARRY: 2.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 2.50 Max: 5.1
Current: 2.31
0.3
5.1

More Statistics

Revenue(Mil) $71
EPS $ -0.04
Beta1.89
Short Percentage of Float14.43%
52-Week Range $2.39 - 8.04
Shares Outstanding(Mil)143.34

Analyst Estimate

Jun16
Revenue(Mil)
EPS($) -0.58
EPS without NRI($) -0.58

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, SZSE:002604, XMCE:ROVI, NAS:CEMP, XBRU:ABLX, ROCO:4105 » details
Traded in other countries:AR2.Germany,
Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Screen: Stocks With Estimated Revenue Up 5% - January Jan 18 2016 
Insider Buys Round-up: Tenet Healthcare and Sprint Corp Aug 14 2015 
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 

More From Other Websites
Q3 2016 Array Biopharma Inc Earnings Release - Before Market Open May 03 2016
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2016 On May 3, 2016 Apr 26 2016
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2016 On May 3, 2016 Apr 26 2016
Why Patents are the Lifeblood of Biotech Companies Apr 25 2016
Array Bio ends late-stage study of ovarian cancer drug Apr 01 2016
Array Bio stops study testing drug for ovarian cancer Apr 01 2016
Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer Apr 01 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 01 2016
Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer Apr 01 2016
Array BioPharma And Asahi Kasei Pharma Corporation Announce Development And Commercialization... Mar 31 2016
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 31 2016
Array BioPharma And Asahi Kasei Pharma Corporation Announce Development And Commercialization... Mar 31 2016
Five Cheap Healthcare Stocks With Hedge Fund Support Mar 24 2016
Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : March 23,... Mar 23 2016
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : March 9,... Mar 09 2016
Array Biopharma draws upside position Mar 08 2016
Array BioPharma To Present At The Cowen And Company Annual Healthcare Conference Mar 01 2016
Edited Transcript of ARRY earnings conference call or presentation 3-Feb-15 2:00pm GMT Feb 29 2016
Small Cap Acquisition Candidates See Increased Investor Interest Feb 16 2016
ARRAY BIOPHARMA INC Financials Feb 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK